LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders
Bordeaux, October 15th, 2018 – LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery, today announced that it has signed an exclusive license agreement with Cornell University (Ithaca, NY, USA )forits Christensenellapatent family.
Christensenellais a recently discovered family of gut bacteria. Considered a keystone taxon in the human gut microbiome, it represents a major opportunity in the fight against obesity, metabolic disorders and other high-impact diseases. Christensenellaand microbiome modulation is an innovative approach with the potential to unlock a wide range of therapeutic applications.
By securing a license for the Christensenellapatent, LNC has bolstered its strategy for developing innovative therapeutic approaches based on this new family of bacteria. “Expanding our intellectual property is essential in order for us to successfully pursue our vision and our development strategy,” said Dr. Georges Rawadi, CEO of LNC.“Securing a license for the Christensenellapatent has reinforced our existing intellectual property portfolio.It’s a key step in establishing our leadership position for the Christensenellafamilyand anticipating its future therapeutic applications.”Symflor, who previously licensed the Christensenllapatent, has assisted LNC in this transaction.
LNC aims to use this license to develop the first Christensenella-based drug candidatefor the treatment of obesity and metabolic disorders. In parallel, LNC will leverage its research platform dedicated to studying this family of bacteria in order to gain deeper insight into how it operates and understand how it interacts with host cells. “We strongly believe that Christensenellahas a wide therapeutic potential that goes beyond obesity and metabolic disorders. We are therefore considering the possibility of broadening our fields of application,” Dr. Rawadi added.
Commited to become a major player in biotechnologies, the company plans to continue building up its intellectual property portfolio and developing academic and/or industry partnerships with research teams working on microbiome-related topics.
In the same category
YSOPIA Successfully Completes Phase 1 Clinical Study of Xla1 Biotherapy for the Treatment of Obesity...
Jul 6, 2021more +
90 seconds to learn more about YSOPIA Bioscience
Jun 1, 2021more +
We are looking for a Senior Scientist in Microbiology & Biotechnology – Team Leader...
May 4, 2021more +